Why Applied Therapeutics has a credibility problem

This story first appeared in Adam’s Biotech Scorecard, a subscriber-only newsletter. STAT+ subscribers can sign up here to get it delivered to their inbox.

Applied Therapeutics’ CEO Shoshana Shendelman has a debilitating credibility problem: She repeatedly misled investors prior to the Food and Drug Administration’s rejection of the company’s rare-disease drug.

Throughout 2024, Shendelman assured investors that Applied’s drug, called govorestat, was sailing through the FDA review process without major hitches. We now know she was lying by omission. The company was aware of  significant problems with the govorestat application identified by the FDA, but Shendelman said nothing publicly. 

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.

Already have an account? Log in

Individual plans

Group plans

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$20

for 3 months, then $399/year

$20 for 3 months Get Started

Then $399/year

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

To read the rest of this story subscribe to STAT+.

Subscribe

Log In